Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1096 | 1096 | 1135 | 1195 | 1551 | 2496 |
Fund Return | 9.57% | 9.57% | 13.53% | 6.12% | 9.18% | 9.58% |
Place in category | 96 | 96 | 337 | 438 | 295 | 79 |
% in Category | 20 | 20 | 63 | 85 | 57 | 20 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Manulife Div incm Fd Sr Adv | 7.49B | 9.57 | 6.13 | 9.59 | ||
Manulife Div incm Fd Sr F | 7.49B | 9.87 | 7.32 | 10.82 | ||
Manulife Div incm Fd Sr FT6 | 7.49B | 9.87 | 7.32 | 10.81 | ||
Manulife Glbl Eq Cl Sr Adv | 7B | 6.62 | 8.74 | 9.95 | ||
Manulife Glbl Eq Cl Sr F | 7B | 6.94 | 10.08 | 11.30 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Fidelity Canadian Growth Comp Sr A | 11.12B | 18.41 | 8.53 | 13.17 | ||
Fidelity Canadian Growth Comp Sr F | 11.12B | 18.80 | 10.02 | 14.71 | ||
Fidelity Canadian Growth Comp Sr B | 11.12B | 18.47 | 8.77 | 13.40 | ||
Manulife Div incm Fd Sr Adv | 7.49B | 9.57 | 6.13 | 9.59 | ||
Manulife Div incm Fd Sr F | 7.49B | 9.87 | 7.32 | 10.82 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
FirstService | CA33767E2024 | 4.05 | 151.62 | -2.05% | |
Thermo Fisher Scientific | US8835561023 | 4.04 | 572.10 | -0.92% | |
Constellation Software | CA21037X1006 | 4.00 | 3,655.01 | -1.13% | |
Visa A | US92826C8394 | 3.96 | 275.22 | +0.07% | |
Canadian Pacific Kansas City | CA13646K1084 | 3.96 | 82.09 | +0.20% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Neutral | Buy |
Technical Indicators | Strong Sell | Neutral | Strong Buy |
Summary | Strong Sell | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review